Tonix Pharmaceuticals (TNXP) Financials

Tonix Pharmaceuticals logo
$2.82 -0.12 (-4.08%)
Closing price 04:00 PM Eastern
Extended Trading
$2.88 +0.06 (+1.95%)
As of 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Tonix Pharmaceuticals

Annual Income Statements for Tonix Pharmaceuticals

This table shows Tonix Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-48 -39 -21 - -31 -52 -92 -117 -117 -130 -124
Consolidated Net Income / (Loss)
-48 -39 -21 - -29 -50 -92 -110 -117 -130 -124
Net Income / (Loss) Continuing Operations
-48 -39 -21 - -29 -50 -92 -110 -117 -130 -124
Total Pre-Tax Income
-48 -39 -21 - -29 -50 -92 -110 -117 -133 -127
Total Operating Income
-48 -39 -21 - -29 -51 -92 -112 -118 -137 -126
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 3.03 2.33 6.47
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 7.77 10 13
Operating Revenue
- - - - - - - - 7.77 10 13
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 4.74 7.77 6.64
Operating Cost of Revenue
- - - - - - - 0.00 4.74 7.77 6.64
Total Operating Expenses
48 39 21 - 29 51 92 112 121 139 132
Selling, General & Admin Expense
13 10 7.95 - 11 14 23 30 35 40 88
Research & Development Expense
36 29 13 - 18 36 69 82 87 40 44
Impairment Charge
- - - - - - - - 0.00 59 0.00
Total Other Income / (Expense), net
0.11 0.13 0.17 - 0.21 0.05 0.03 1.87 1.72 4.07 -1.33
Interest Expense
- - - - - - - - - 1.23 2.18
Interest & Investment Income
0.11 0.13 0.17 - 0.21 0.05 0.03 1.87 - 0.02 4.15
Other Income / (Expense), net
- - - - - - - - 1.72 5.28 -3.30
Income Tax Expense
- - - - - - - - 0.00 -2.59 -3.01
Basic Earnings per Share
($28.62) ($15.41) ($31.69) - ($19.33) ($0.55) ($8.10) ($20.01) ($14,720.25) ($176.60) ($14.57)
Weighted Average Basic Shares Outstanding
1.68M 2.52M 666.51K 1.09M 1.61M 94.59M 11.39M 5.84M 7.93K 736.34K 8.51M
Diluted Earnings per Share
($28.62) ($15.41) ($31.69) - ($19.33) ($0.55) ($8.10) ($20.01) ($14,720.25) ($176.60) ($14.57)
Weighted Average Diluted Shares Outstanding
1.68M 2.52M 666.51K 1.09M 1.61M 94.59M 11.39M 5.84M 7.93K 736.34K 8.51M
Weighted Average Basic & Diluted Shares Outstanding
1.68M 2.52M 666.51K 1.09M 1.61M 94.59M 360.22M 62.54M - 6.43M 13.41M

Quarterly Income Statements for Tonix Pharmaceuticals

This table shows Tonix Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-15 -79 -14 -22 -17 -28 -32 -47 -40 -41 -53
Consolidated Net Income / (Loss)
-15 -79 -14 -22 -17 -28 -32 -47 -40 -41 -53
Net Income / (Loss) Continuing Operations
-15 -79 -14 -22 -17 -28 -32 -47 -40 -41 -53
Total Pre-Tax Income
-15 -79 -16 -24 -18 -29 -33 -47 -40 -41 -54
Total Operating Income
-21 -77 -16 -22 -16 -28 -33 -48 -42 -43 -55
Total Gross Profit
0.82 -1.16 1.27 1.40 1.49 -1.27 1.92 4.33 5.30 13 16
Total Revenue
2.48 2.21 2.82 2.58 2.43 2.00 3.29 5.39 6.88 14 17
Operating Revenue
2.48 2.21 2.82 2.58 2.43 2.00 3.29 5.39 6.88 14 17
Total Cost of Revenue
1.66 3.37 1.56 1.18 0.94 3.27 1.37 1.06 1.58 0.70 1.25
Operating Cost of Revenue
1.66 3.37 1.56 1.18 0.94 3.27 1.37 1.06 1.58 0.70 1.25
Total Operating Expenses
22 76 17 24 18 27 35 53 47 55 71
Selling, General & Admin Expense
9.31 7.50 7.71 16 10 16 26 36 29 36 46
Research & Development Expense
13 9.70 9.11 8.30 7.44 11 9.29 17 18 19 26
Total Other Income / (Expense), net
6.41 -1.46 -0.33 -1.75 -1.70 -1.01 0.08 1.31 1.34 1.38 1.44
Interest Expense
0.00 0.00 0.30 - 2.09 0.00 0.00 0.09 0.00 0.00 0.00
Interest & Investment Income
- 0.00 0.02 - 0.39 0.94 1.23 - 1.35 1.43 1.36
Other Income / (Expense), net
6.41 -1.46 -0.04 -1.75 0.00 -1.96 -1.16 -0.58 -0.00 -0.05 0.08
Income Tax Expense
0.00 0.00 -1.67 - -0.92 -1.04 -0.98 -0.07 0.00 -0.60 -0.67
Basic Earnings per Share
($535.72) ($1,920.85) ($22.68) ($30.02) ($2.84) ($3.86) ($3.59) ($5.51) ($2.93) ($2.44) ($2.89)
Weighted Average Basic Shares Outstanding
27.89K 41.01K 626.67K 736.34K 5.93M 7.33M 8.92M 8.51M 13.71M 16.64M 18.44M
Diluted Earnings per Share
($535.72) ($1,920.85) ($22.68) ($30.02) ($2.84) ($3.86) ($3.59) ($5.51) ($2.93) ($2.44) ($2.89)
Weighted Average Diluted Shares Outstanding
27.89K 41.01K 626.67K 736.34K 5.93M 7.33M 8.92M 8.51M 13.71M 16.64M 18.44M
Weighted Average Basic & Diluted Shares Outstanding
95.54M 22.00M 186.89M 6.43M 7.32M 8.77M 11.78M 13.41M 15.94M 17.15M 19.43M

Annual Cash Flow Statements for Tonix Pharmaceuticals

This table details how cash moves in and out of Tonix Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-19 -0.28 6.56 -0.45 -14 66 102 -58 -95 74 110
Net Cash From Operating Activities
-43 -37 -19 -24 -27 -49 -76 -98 -102 -61 -100
Net Cash From Continuing Operating Activities
-43 -37 -19 -24 -27 -49 -76 -98 -102 -61 -100
Net Income / (Loss) Continuing Operations
-48 -39 -21 -26 -29 -50 -92 -110 -117 -130 -124
Consolidated Net Income / (Loss)
-48 -39 -21 -26 -29 -50 -92 -110 -117 -130 -124
Depreciation Expense
0.16 0.21 0.07 0.05 0.03 0.03 0.05 1.25 4.29 3.42 1.93
Amortization Expense
- - - - - - - - 0.00 0.84 1.90
Non-Cash Adjustments To Reconcile Net Income
4.38 3.40 1.79 1.63 1.46 4.29 11 11 10 59 9.67
Changes in Operating Assets and Liabilities, net
0.99 -2.08 0.14 0.44 0.45 -2.42 5.79 -0.00 -0.07 5.79 11
Net Cash From Investing Activities
-24 17 7.17 -0.01 -0.02 -8.56 -35 -48 -29 -0.12 -4.53
Net Cash From Continuing Investing Activities
-24 17 7.17 -0.01 -0.02 -8.56 -35 -48 -29 -0.12 -4.53
Purchase of Property, Plant & Equipment
-0.12 -0.07 - -0.01 -0.02 -8.56 -35 -48 -7.90 -0.12 -3.37
Sale and/or Maturity of Investments
4.71 17 7.17 - - - - - - 0.00 0.85
Other Investing Activities, net
0.00 - - - - - - - - 0.00 -2.01
Net Cash From Financing Activities
48 20 19 24 13 123 212 88 37 135 215
Net Cash From Continuing Financing Activities
48 20 19 24 13 123 212 88 37 135 215
Repayment of Debt
- - - - - - - - 0.00 -2.35 -9.65
Repurchase of Common Equity
- - - - - - - 0.00 -14 0.00 -14
Payment of Dividends
- - - - - - - - 0.00 -3.00 0.00
Issuance of Common Equity
48 20 19 13 5.87 109 212 95 42 140 238
Effect of Exchange Rate Changes
-0.00 -0.01 -0.01 -0.01 - -0.02 -0.03 -0.07 -0.07 0.00 -0.03
Cash Interest Paid
- - - - - - - - 0.09 1.23 0.09

Quarterly Cash Flow Statements for Tonix Pharmaceuticals

This table details how cash moves in and out of Tonix Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-18 -2.89 24 71 33 -6.38 65 18 -24 -9.39 -13
Net Cash From Operating Activities
-18 -9.92 -19 -15 -17 -15 -29 -40 -42 -42 -41
Net Cash From Continuing Operating Activities
-18 -9.92 -19 -15 -17 -15 -29 -40 -42 -42 -41
Net Income / (Loss) Continuing Operations
-15 -79 -14 -22 -17 -28 -32 -47 -40 -41 -53
Consolidated Net Income / (Loss)
-15 -79 -14 -22 -17 -28 -32 -47 -40 -41 -53
Depreciation Expense
1.21 1.21 0.51 0.50 0.49 0.48 0.46 0.49 0.56 0.62 0.64
Non-Cash Adjustments To Reconcile Net Income
-5.31 63 1.31 0.36 2.97 3.70 2.16 0.84 2.05 2.34 2.37
Changes in Operating Assets and Liabilities, net
1.17 4.82 -6.62 6.42 -3.28 7.42 0.60 5.94 -4.73 -4.65 9.24
Net Cash From Investing Activities
-0.11 - -0.01 -0.00 -0.01 -2.54 -0.96 -1.02 -1.69 -0.59 -0.60
Net Cash From Continuing Investing Activities
-0.11 - -0.01 -0.00 -0.01 -2.54 -0.96 -1.02 -1.69 -0.59 -0.60
Purchase of Property, Plant & Equipment
-0.11 - -0.01 -0.00 -0.01 -0.53 -0.96 -1.87 -1.69 -0.59 -0.60
Net Cash From Financing Activities
-0.21 7.03 43 85 50 11 95 59 20 34 28
Net Cash From Continuing Financing Activities
-0.21 7.03 43 85 50 11 95 59 20 33 28
Issuance of Common Equity
0.02 11 44 86 62 14 95 67 20 33 28
Other Financing Activities, net
- - - - - - - - - - 0.04
Effect of Exchange Rate Changes
-0.00 0.00 - 0.02 -0.01 -0.00 -0.00 -0.01 0.01 -0.06 -0.04

Annual Balance Sheets for Tonix Pharmaceuticals

This table presents Tonix Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
47 28 27 26 15 98 241 226 154 163 277
Total Current Assets
46 27 26 26 14 88 189 131 48 119 229
Cash & Equivalents
19 19 25 25 11 77 179 120 25 99 208
Accounts Receivable
- - - - - - - - 0.00 3.68 6.27
Inventories, net
- - - - - - - 0.00 14 8.41 6.01
Prepaid Expenses
3.34 1.02 0.95 1.02 2.70 11 10 11 9.18 8.14 8.96
Plant, Property, & Equipment, net
0.35 0.15 0.09 0.04 0.03 8.57 51 94 94 42 44
Total Noncurrent Assets
0.31 0.22 0.22 0.22 0.58 1.62 1.29 1.10 13 1.64 3.84
Other Noncurrent Operating Assets
0.06 0.01 0.01 0.00 0.36 1.26 1.29 0.98 1.95 1.52 3.84
Total Liabilities & Shareholders' Equity
47 28 27 26 15 98 241 226 154 163 277
Total Liabilities
6.76 2.15 2.14 2.66 5.14 11 22 19 49 23 32
Total Current Liabilities
6.65 2.12 2.13 2.66 5.14 9.82 22 18 19 18 31
Accounts Payable
3.05 0.87 1.30 2.66 4.78 9.22 21 18 16 15 31
Other Current Liabilities
- - - 0.00 0.35 0.60 0.49 0.43 0.27 0.27 0.13
Total Noncurrent Liabilities
0.11 0.03 0.01 0.00 0.01 0.72 0.47 0.33 30 5.03 1.18
Other Noncurrent Operating Liabilities
- - - 0.00 0.01 0.72 0.47 0.33 23 0.36 1.18
Commitments & Contingencies
0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
40 25 25 24 9.42 88 219 207 106 140 245
Total Preferred & Common Equity
40 25 25 24 9.42 88 219 207 106 140 245
Preferred Stock
0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
40 25 25 24 9.42 88 219 207 106 140 245
Common Stock
143 167 187 212 227 355 579 677 706 871 1,100
Retained Earnings
-102 -141 -162 -188 -217 -268 -360 -470 -601 -731 -855
Accumulated Other Comprehensive Income / (Loss)
-0.02 -0.01 -0.01 -0.04 -0.05 -0.06 -0.09 -0.17 -0.23 -0.26 -0.29

Quarterly Balance Sheets for Tonix Pharmaceuticals

This table presents Tonix Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
139 135 70 95 193 187 252 258 254 242
Total Current Assets
31 30 25 51 150 144 208 207 203 192
Cash & Equivalents
6.91 7.05 4.16 28 132 125 190 185 176 163
Accounts Receivable
1.56 - 3.34 4.01 3.31 2.32 3.48 8.82 12 15
Inventories, net
13 12 9.46 7.93 8.14 5.99 5.73 3.65 4.68 4.48
Prepaid Expenses
9.54 11 8.34 10 6.41 9.90 8.81 9.23 11 10
Plant, Property, & Equipment, net
95 93 43 43 42 42 43 45 45 45
Total Noncurrent Assets
13 12 1.77 1.70 1.53 1.49 1.80 5.85 5.90 5.40
Other Noncurrent Operating Assets
2.13 1.72 1.65 1.58 1.41 1.37 1.68 5.73 5.90 5.40
Total Liabilities & Shareholders' Equity
139 135 70 95 193 187 252 258 254 242
Total Liabilities
18 27 28 21 12 19 21 31 32 43
Total Current Liabilities
18 20 22 15 12 19 21 30 31 42
Accounts Payable
17 17 19 12 12 19 21 29 31 42
Other Current Liabilities
0.43 0.28 0.28 0.28 0.24 0.20 0.16 0.16 0.25 0.34
Total Noncurrent Liabilities
0.72 6.72 6.16 5.60 0.33 0.30 0.27 1.13 1.02 0.92
Other Noncurrent Operating Liabilities
- 0.00 0.49 0.43 0.33 0.30 0.27 1.13 1.02 0.92
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
121 108 42 74 180 168 231 227 222 199
Total Preferred & Common Equity
121 108 42 74 180 168 231 227 222 199
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
121 108 42 74 180 168 231 227 222 199
Common Stock
694 724 737 783 928 944 1,039 1,122 1,158 1,189
Retained Earnings
-573 -616 -694 -709 -748 -776 -808 -895 -935 -989
Accumulated Other Comprehensive Income / (Loss)
-0.22 -0.24 -0.24 -0.25 -0.27 -0.27 -0.27 -0.28 -0.35 -0.39

Annual Metrics And Ratios for Tonix Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Tonix Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
18,831,669.00 39,181,106.00 7,830,040.00 14,203,444.00 1,575,246.00 156,585,050.00 439,590,272.00 57,536,293.00 23,849,341.00 - 11,776,542.00
DEI Adjusted Shares Outstanding
0.00 0.00 0.00 0.00 2.00 245.00 687.00 2,877.00 7,453.00 - 11,776,542.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 0.00 0.00 -15,546,000.00 -212,955.10 -134,333.33 -40,624.61 -15,652.49 - -10.53
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.94% 29.85%
EBITDA Growth
-73.79% 0.00% 45.25% 100.25% -53,437.04% -75.28% -82.75% -20.13% -1.38% -14.24% 1.56%
EBIT Growth
-74.15% 0.00% 45.36% 100.00% 0.00% -75.22% -82.76% -21.43% -4.07% -13.69% 1.84%
NOPAT Growth
-74.15% 0.00% 45.36% 100.00% 0.00% -75.22% -82.76% -21.43% -5.61% -15.48% 8.05%
Net Income Growth
-74.01% 0.00% 45.62% 0.00% 0.00% -76.33% -82.88% -19.43% -5.84% -11.47% 4.63%
EPS Growth
-74.01% 0.00% 45.62% 0.00% 0.00% 97.15% -82.88% -19.43% -5.84% -11.47% 91.75%
Operating Cash Flow Growth
-86.20% 12.26% 48.74% -25.32% -11.31% -82.01% -55.58% -29.77% -4.03% 40.27% -63.88%
Free Cash Flow Firm Growth
-77.66% 0.00% 0.00% 103.39% -4,035.65% -141.56% -98.06% -32.89% 31.88% 36.22% -41.79%
Invested Capital Growth
-29.71% 0.00% -14.13% -51.70% -31.43% 635.20% 287.40% 117.07% 2.92% -46.06% -22.28%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 94.74% -10.60% 27.26%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 100.22% -90,106.25% -19.64% -15.58% -2.25% 6.29% 6.55% -25.91%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 100.00% 0.00% -19.63% -15.60% -2.99% 5.75% 6.30% -24.70%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 100.00% 0.00% -19.63% -15.60% -2.99% 4.36% 3.43% -25.83%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -19.73% -15.71% -1.97% 3.60% 3.86% -25.00%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -52.78% -15.71% -1.97% 3.60% 3.86% -31.03%
Operating Cash Flow Q/Q Growth
-9.51% 14.78% 2.62% -8.59% 0.53% -17.49% -12.73% 0.15% -0.04% 11.23% -33.44%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% -2,380.20% -30.51% -38.25% 14.21% 23.98% -41.78% -35.39%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% -38.16% -618.22% 55.00% 110.74% -2.24% -21.94% -10.56% -8.70%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 38.97% 23.07% 49.34%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,446.54% -1,271.74% -954.99%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,523.94% -1,354.28% -959.05%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,501.78% -1,313.95% -984.19%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,501.78% -1,288.25% -946.22%
Tax Burden Percent
100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 98.04% 97.63%
Interest Burden Percent
99.78% 99.67% 99.21% 0.00% 99.27% 99.91% 99.97% 98.33% 100.00% 100.00% 98.48%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -93.93% -138.93% -205.15%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -44.33% -74.93% -181.05%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.32% 32.81% 140.68%
Return on Equity (ROE)
-125.87% -118.38% -84.53% 0.00% -173.02% -103.98% -60.25% -51.76% -74.61% -106.12% -64.48%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -460.64% -374.37% -197.40% -96.80% -79.08% -180.08%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -61.38% -83.59% -58.63%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -61.38% -81.95% -56.37%
Return on Common Equity (ROCE)
-125.87% -118.38% -84.53% 0.00% -173.02% -103.98% -60.25% -51.76% -74.61% -106.12% -64.48%
Return on Equity Simple (ROE_SIMPLE)
-119.35% -153.16% -85.81% 0.00% -303.90% -57.57% -42.19% -53.20% -110.55% -93.18% 0.00%
Net Operating Profit after Tax (NOPAT)
-34 -27 -15 0.00 -20 -35 -65 -78 -83 -96 -88
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,066.76% -948.00% -671.34%
Net Nonoperating Expense Percent (NNEP)
-35.21% -44.12% -24.02% 0.00% -46.26% -34.08% -21.62% -21.25% -49.60% -64.00% -24.11%
Return On Investment Capital (ROIC_SIMPLE)
-83.74% - - - - - - - -72.41% -65.08% -35.89%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 61.03% 76.93% 50.66%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 447.37% 397.28% 668.99%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,115.54% 396.00% 339.41%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,562.91% 1,377.35% 1,008.39%
Earnings before Interest and Taxes (EBIT)
-48 -39 -21 0.00 -29 -51 -92 -112 -117 -133 -129
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-48 -39 -21 0.05 -29 -50 -92 -111 -112 -128 -125
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.59 0.73 1.10 0.13 0.20 1.21 0.72 0.11 0.09 0.44 0.75
Price to Tangible Book Value (P/TBV)
3.60 0.73 1.10 0.13 0.20 1.21 0.72 0.11 0.10 0.44 0.75
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.24 6.11 14.03
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 2.77 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.05 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.03 0.00
Financial Leverage
-1.07 -1.03 -1.04 -1.05 -1.10 -0.91 -0.84 -0.70 -0.44 -0.44 -0.78
Leverage Ratio
1.13 1.14 1.09 1.10 1.24 1.16 1.11 1.10 1.22 1.29 1.14
Compound Leverage Factor
1.13 1.13 1.08 0.00 1.23 1.16 1.11 1.08 1.22 1.29 1.13
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.79% 5.09% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.05% 1.92% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.73% 3.17% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 92.21% 94.91% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.08 -0.06 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.14 0.71 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.06 -0.04 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.11 -0.08 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.95 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.08 -0.05 0.00
Altman Z-Score
7.41 -5.63 -2.45 -8.25 -26.47 1.46 1.73 -3.23 -7.54 -6.58 -1.50
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
6.97 12.83 12.44 9.81 2.72 8.96 8.71 7.19 2.53 6.50 7.42
Quick Ratio
6.47 12.34 11.99 9.43 2.19 7.85 8.23 6.61 1.32 5.60 6.94
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-33 0.00 -15 0.50 -20 -48 -94 -125 -85 -54 -77
Operating Cash Flow to CapEx
-36,040.68% -56,534.85% 0.00% -399,516.67% -156,958.82% -567.09% -214.00% -203.65% -1,479.16% -50,770.83% -2,963.61%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -35.41
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -45.78
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -47.32
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.06 0.06
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.63
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.70 0.92
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.15 0.30
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.28 0.49 0.29
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 138.60
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 518.17 396.36
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,309.26 739.80 1,262.25
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,309.26 -221.63 -727.29
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.89 -0.85 -0.97 -1.47 -1.93 10 40 87 89 48 38
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.15 0.31
Increase / (Decrease) in Invested Capital
-0.66 0.00 -0.12 -0.50 -0.46 12 30 47 2.54 -41 -11
Enterprise Value (EV)
101 -7.70 1.52 -22 -9.41 29 -21 -98 -6.43 -30 -24
Market Capitalization
144 18 27 3.12 1.84 106 157 22 9.61 62 184
Book Value per Share
$2.14 $0.65 $3.14 $1.67 $5.98 $0.56 $0.50 $3.60 $4.42 $0.75 $20.82
Tangible Book Value per Share
$2.13 $0.64 $3.13 $1.66 $5.90 $0.56 $0.50 $3.60 $3.98 $0.75 $20.81
Total Capital
40 25 25 24 9.42 88 219 207 114 147 245
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.91 7.49 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.56 4.67 0.00
Net Debt
-43 -26 -25 -25 -11 -77 -179 -120 -16 -91 -208
Capital Expenditures (CapEx)
0.12 0.07 -0.01 0.01 0.02 8.56 35 48 6.90 0.12 3.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.31 -1.10 -1.18 -1.63 -2.44 1.10 -11 -7.63 6.29 4.74 -9.60
Debt-free Net Working Capital (DFNWC)
40 25 24 23 8.81 78 167 113 31 104 198
Net Working Capital (NWC)
40 25 24 23 8.81 78 167 113 29 101 198
Net Nonoperating Expense (NNE)
14 12 6.22 0.00 8.44 15 28 32 34 34 36
Net Nonoperating Obligations (NNO)
-43 -26 -26 -25 -11 -77 -179 -120 -16 -91 -208
Total Depreciation and Amortization (D&A)
0.16 0.21 0.07 0.05 0.03 0.03 0.05 1.25 4.29 4.26 3.83
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 80.92% 46.95% -73.23%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 402.09% 1,025.51% 1,510.94%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 371.83% 997.57% 1,510.94%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1,830,400,000.00) ($9,862,400.00) ($2,028,800.00) ($1,715,840.00) $0.00 ($3,520.00) ($1,664.00) ($654.00) ($21,920.00) ($176.60) ($14.57)
Adjusted Weighted Average Basic Shares Outstanding
0.00 4.00 12.00 95.00 7.71K 50.61K 83.43K 178.70K 5.33K 736.34K 8.51M
Adjusted Diluted Earnings per Share
($1,830,400,000.00) ($9,862,400.00) ($2,028,800.00) ($1,715,840.00) $0.00 ($3,520.00) ($1,664.00) ($654.00) ($21,920.00) ($176.60) ($14.57)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 4.00 12.00 95.00 7.71K 50.61K 83.43K 178.70K 5.33K 736.34K 8.51M
Adjusted Basic & Diluted Earnings per Share
($1,830,400,000.00) ($9,862,400.00) ($2,028,800.00) ($1,715,840.00) $0.00 ($3,520.00) ($1,664.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 4.00 10.00 17.00 7.71K 14.78K 56.28K 312.70K 0.00 6.43M 13.41M
Normalized Net Operating Profit after Tax (NOPAT)
-34 -27 -15 0.00 -20 -35 -65 -78 -83 -54 -88
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,066.76% -539.14% -671.34%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,501.78% -1,313.95% -969.20%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -59.15
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -40.34
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -60.69
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -41.89
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.31% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11.97% -2.31% -11.09%

Quarterly Metrics And Ratios for Tonix Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Tonix Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
23,849,341.00 95,543,805.00 22,004,159.00 - 6,434,881.00 7,324,670.00 8,765,896.00 11,776,542.00 13,405,401.00 15,940,801.00 17,151,024.00
DEI Adjusted Shares Outstanding
7,453.00 29,857.00 220,042.00 - 6,434,881.00 7,324,670.00 8,765,896.00 11,776,542.00 13,405,401.00 15,940,801.00 17,151,024.00
DEI Earnings Per Adjusted Shares Outstanding
-2,004.43 -2,638.44 -64.59 - -2.62 -3.86 -3.65 -3.98 -3.00 -2.54 -3.11
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% -29.26% -31.68% -2.14% -9.51% 16.58% 108.75% 183.16% 577.88% 423.83%
EBITDA Growth
59.32% -175.78% 44.75% 3.33% -15.41% 63.93% -126.91% -125.97% -164.49% -50.25% -62.06%
EBIT Growth
55.93% -171.63% 44.58% 5.37% -7.46% 61.60% -119.41% -121.06% -158.75% -40.77% -61.75%
NOPAT Growth
37.02% -166.59% 44.74% 17.74% 24.81% 63.40% -112.59% -114.80% -158.73% -50.32% -67.64%
Net Income Growth
54.74% -177.81% 49.19% 19.08% -12.65% 64.11% -125.22% -112.19% -138.84% -43.44% -66.60%
EPS Growth
54.74% -177.81% 49.19% 19.08% 99.47% 99.80% 84.17% 81.65% -3.17% 36.79% 19.50%
Operating Cash Flow Growth
46.60% 57.55% 19.60% 34.51% 5.67% -49.54% -53.09% -171.02% -155.25% -184.79% -42.71%
Free Cash Flow Firm Growth
35.79% 127.10% 209.66% 217.62% 257.86% -212.26% -120.62% -190.43% -143.50% -106.66% -235.19%
Invested Capital Growth
18.39% -59.57% -52.92% -46.06% -56.00% -8.11% -23.87% -22.28% -14.41% 7.92% -10.70%
Revenue Q/Q Growth
-34.32% -11.04% 27.81% -8.50% -5.93% -17.74% 64.66% 63.83% 27.61% 96.92% 27.24%
EBITDA Q/Q Growth
44.85% -476.77% 80.79% -55.23% 27.62% -84.95% -20.88% -43.29% 15.28% -2.39% -30.38%
EBIT Q/Q Growth
41.66% -427.32% 80.20% -52.58% 27.37% -93.17% -13.13% -42.78% 14.99% -2.51% -29.99%
NOPAT Q/Q Growth
21.87% -262.12% 79.88% -44.53% 28.59% -76.26% -16.86% -46.02% 13.98% -2.40% -30.32%
Net Income Q/Q Growth
45.32% -427.32% 81.96% -55.55% 23.88% -68.00% -13.22% -46.55% 14.32% -0.89% -31.51%
EPS Q/Q Growth
45.32% -427.32% 81.96% -55.55% 90.54% -35.92% 6.99% -53.48% 46.82% 16.72% -18.44%
Operating Cash Flow Q/Q Growth
21.33% 43.56% -89.55% 22.19% -13.32% 10.53% -94.04% -37.76% -6.73% 0.18% 2.77%
Free Cash Flow Firm Q/Q Growth
-48.30% 144.48% 248.34% -48.81% 99.02% -131.63% 36.01% -124.50% 4.26% -50.27% -3.78%
Invested Capital Q/Q Growth
23.63% -58.03% 16.23% -10.56% 0.85% -12.35% -3.71% -8.70% 11.07% 10.52% -20.32%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
33.12% -52.49% 44.90% 54.18% 61.18% -63.76% 58.45% 80.37% 77.06% 94.81% 92.74%
EBITDA Margin
-540.98% -3,507.38% -527.25% -911.54% -637.96% -1,397.95% -1,026.20% -897.51% -595.89% -309.84% -317.48%
Operating Margin
-860.23% -3,501.63% -551.17% -870.64% -660.93% -1,416.22% -1,005.08% -895.84% -603.91% -314.05% -321.64%
EBIT Margin
-601.89% -3,567.80% -552.73% -938.50% -660.93% -1,514.06% -1,040.21% -906.57% -603.95% -314.41% -321.21%
Profit (Net Income) Margin
-601.89% -3,567.75% -503.65% -856.24% -692.84% -1,415.02% -972.95% -870.32% -584.39% -299.41% -309.44%
Tax Burden Percent
100.00% 100.00% 89.50% 91.23% 94.80% 96.47% 97.02% 99.85% 100.00% 98.54% 98.77%
Interest Burden Percent
100.00% 100.00% 101.81% 100.00% 110.58% 96.88% 96.40% 96.15% 96.76% 96.64% 97.54%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-60.49% -378.67% -51.67% -89.31% -58.32% -218.75% -152.45% -191.63% -164.29% -144.22% -249.21%
ROIC Less NNEP Spread (ROIC-NNEP)
-60.51% -147.01% -26.52% -77.44% -49.66% -204.76% -144.02% -182.86% -157.28% -137.08% -240.98%
Return on Net Nonoperating Assets (RNNOA)
15.37% 17.14% 3.60% 33.91% 22.24% 117.92% 99.19% 142.09% 122.41% 105.92% 197.45%
Return on Equity (ROE)
-45.12% -361.53% -48.08% -55.40% -36.08% -100.83% -53.26% -49.55% -41.88% -38.31% -51.76%
Cash Return on Invested Capital (CROIC)
-89.44% -48.97% -45.57% -79.08% -37.70% -120.99% -120.02% -180.08% -218.75% -268.66% -326.71%
Operating Return on Assets (OROA)
-39.24% -386.43% -53.28% -59.70% -40.44% -115.54% -61.67% -54.00% -47.04% -41.45% -55.88%
Return on Assets (ROA)
-39.24% -386.42% -48.55% -54.47% -42.39% -107.98% -57.68% -51.84% -45.52% -39.48% -53.83%
Return on Common Equity (ROCE)
-45.12% -361.53% -48.08% -55.40% -36.08% -100.83% -53.26% -49.55% -41.88% -38.31% -51.76%
Return on Equity Simple (ROE_SIMPLE)
-91.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-15 -54 -11 -16 -11 -20 -23 -34 -29 -30 -39
NOPAT Margin
-602.16% -2,451.14% -385.82% -609.45% -462.65% -991.35% -703.55% -627.09% -422.74% -219.84% -225.15%
Net Nonoperating Expense Percent (NNEP)
0.02% -231.66% -25.15% -11.87% -8.65% -13.99% -8.43% -8.77% -7.01% -7.15% -8.23%
Return On Investment Capital (ROIC_SIMPLE)
-12.70% -106.98% -13.25% -10.70% -6.23% -11.79% -10.01% -13.79% -12.80% -13.40% -19.45%
Cost of Revenue to Revenue
66.88% 152.49% 55.10% 45.82% 38.82% 163.76% 41.55% 19.63% 22.94% 5.19% 7.26%
SG&A Expenses to Revenue
375.10% 339.76% 273.10% 603.49% 415.97% 810.91% 781.19% 661.91% 416.17% 265.50% 264.54%
R&D to Revenue
518.25% 439.22% 322.96% 321.34% 306.13% 541.54% 282.34% 314.30% 264.80% 143.36% 149.84%
Operating Expenses to Revenue
893.35% 3,449.14% 596.07% 924.83% 722.11% 1,352.45% 1,063.53% 976.22% 680.97% 408.86% 414.38%
Earnings before Interest and Taxes (EBIT)
-15 -79 -16 -24 -16 -30 -34 -49 -42 -43 -55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -77 -15 -24 -15 -28 -34 -48 -41 -42 -55
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.04 0.05 0.04 0.44 0.64 1.57 0.92 0.75 0.81 0.92 0.84
Price to Tangible Book Value (P/TBV)
0.05 0.05 0.04 0.44 0.64 1.57 0.92 0.75 0.81 0.92 0.84
Price to Revenue (P/Rev)
0.43 0.17 0.29 6.11 11.46 26.81 20.56 14.03 10.50 6.99 3.88
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.06 0.14 0.00 0.00 0.00 3.24 0.53 0.00 0.00 0.59 0.12
Enterprise Value to Revenue (EV/Rev)
0.68 0.51 0.00 0.00 0.00 14.06 2.11 0.00 0.00 0.93 0.10
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.09 0.20 0.11 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.06 0.13 0.07 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.25 -0.12 -0.14 -0.44 -0.45 -0.58 -0.69 -0.78 -0.78 -0.77 -0.82
Leverage Ratio
1.15 1.26 1.20 1.29 1.14 1.23 1.14 1.14 1.11 1.13 1.15
Compound Leverage Factor
1.15 1.26 1.22 1.29 1.26 1.19 1.10 1.10 1.07 1.09 1.12
Debt to Total Capital
8.11% 16.78% 9.72% 5.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
2.40% 5.57% 3.43% 1.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
5.71% 11.20% 6.29% 3.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
91.89% 83.22% 90.28% 94.91% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
-0.10 -0.06 -0.06 -0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
-0.03 -0.03 0.16 0.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.07 -0.04 -0.04 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.13 -0.08 -0.08 -0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
-0.03 -0.04 0.20 0.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.09 -0.05 -0.05 -0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-6.47 -17.25 -10.33 -4.38 0.74 2.69 1.97 -0.55 -0.90 -0.94 -3.21
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.47 1.15 3.33 6.50 12.31 7.53 9.89 7.42 6.99 6.61 4.57
Quick Ratio
0.34 0.34 2.12 5.60 11.12 6.70 9.20 6.94 6.55 6.11 4.22
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-32 14 50 25 51 -16 -10 -23 -22 -33 -34
Operating Cash Flow to CapEx
-16,273.15% 0.00% -208,900.00% -487,666.67% -276,316.67% -2,814.61% -2,991.89% -2,115.80% -2,501.06% -7,196.42% -6,811.61%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 165.37 0.00 24.24 0.00 0.00 -258.92 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 -62.46 0.00 -7.93 0.00 0.00 -445.51 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -62.49 0.00 -7.93 0.00 0.00 -466.56 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.07 0.11 0.10 0.06 0.06 0.08 0.06 0.06 0.08 0.13 0.17
Accounts Receivable Turnover
0.00 0.00 4.05 0.00 0.00 3.47 2.75 2.63 2.89 4.12 4.76
Inventory Turnover
0.00 0.84 0.84 0.70 0.69 0.90 0.99 0.92 1.24 0.88 0.90
Fixed Asset Turnover
0.11 0.18 0.16 0.15 0.15 0.23 0.24 0.30 0.41 0.67 0.98
Accounts Payable Turnover
0.43 0.53 0.61 0.49 0.48 0.37 0.41 0.29 0.35 0.19 0.15
Days Sales Outstanding (DSO)
0.00 0.00 90.11 0.00 0.00 105.05 132.79 138.60 126.12 88.58 76.65
Days Inventory Outstanding (DIO)
0.00 432.65 433.32 518.17 530.49 405.34 368.51 396.36 295.54 413.55 405.75
Days Payable Outstanding (DPO)
855.82 690.39 599.26 739.80 758.51 992.48 889.11 1,262.25 1,038.46 1,915.78 2,486.87
Cash Conversion Cycle (CCC)
-855.82 -257.74 -75.83 -221.63 -228.02 -482.08 -387.81 -727.29 -616.80 -1,413.65 -2,004.47
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
111 46 54 48 49 43 41 38 42 46 37
Invested Capital Turnover
0.10 0.15 0.13 0.15 0.13 0.22 0.22 0.31 0.39 0.66 1.11
Increase / (Decrease) in Invested Capital
17 -68 -61 -41 -62 -3.77 -13 -11 -7.01 3.38 -4.40
Enterprise Value (EV)
6.93 6.41 -17 -30 -17 138 22 -24 -1.15 27 4.26
Market Capitalization
4.44 2.08 3.27 62 115 264 212 184 184 203 167
Book Value per Share
$4.53 $0.44 $3.37 $0.75 $28.03 $22.94 $26.37 $20.82 $16.94 $13.94 $11.63
Tangible Book Value per Share
$4.10 $0.44 $3.37 $0.75 $28.02 $22.92 $26.35 $20.81 $16.93 $13.94 $11.63
Total Capital
118 51 82 147 180 168 231 245 227 222 199
Total Debt
9.54 8.49 7.99 7.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
6.72 5.67 5.17 4.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
2.49 4.33 -20 -91 -132 -125 -190 -208 -185 -176 -163
Capital Expenditures (CapEx)
0.11 0.00 0.01 0.00 0.01 0.53 0.96 1.87 1.69 0.59 0.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)
5.39 1.91 9.95 4.74 5.71 -0.86 -3.02 -9.60 -7.95 -3.59 -13
Debt-free Net Working Capital (DFNWC)
12 6.06 38 104 137 124 187 198 178 173 150
Net Working Capital (NWC)
9.62 3.24 35 101 137 124 187 198 178 173 150
Net Nonoperating Expense (NNE)
-0.01 25 3.33 6.37 5.59 8.46 8.86 13 11 11 15
Net Nonoperating Obligations (NNO)
2.49 4.33 -20 -91 -132 -125 -190 -208 -185 -176 -163
Total Depreciation and Amortization (D&A)
1.51 1.33 0.72 0.70 0.56 2.32 0.46 0.49 0.56 0.62 0.64
Debt-free, Cash-free Net Working Capital to Revenue
52.59% 15.32% 88.11% 46.95% 56.88% -8.72% -29.27% -73.23% -45.28% -12.32% -29.47%
Debt-free Net Working Capital to Revenue
121.36% 48.68% 338.16% 1,025.51% 1,368.66% 1,266.14% 1,816.10% 1,510.94% 1,011.17% 593.25% 348.72%
Net Working Capital to Revenue
93.84% 26.04% 313.19% 997.57% 1,368.66% 1,266.14% 1,816.10% 1,510.94% 1,011.17% 593.25% 348.72%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($576.00) ($1,928.00) ($23.00) ($3,002.00) ($2.84) ($3.86) ($3.59) ($5.51) ($2.93) ($2.44) ($2.89)
Adjusted Weighted Average Basic Shares Outstanding
25.28K 40.85K 621.22K 7.36K 5.93M 7.33M 8.92M 8.51M 13.71M 16.64M 18.44M
Adjusted Diluted Earnings per Share
($576.00) ($1,928.00) ($23.00) ($3,002.00) ($2.84) ($3.86) ($3.59) ($5.51) ($2.93) ($2.44) ($2.89)
Adjusted Weighted Average Diluted Shares Outstanding
25.28K 40.85K 621.22K 7.36K 5.93M 7.33M 8.92M 8.51M 13.71M 16.64M 18.44M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($3,002.00) $0.00 $0.00 $0.00 ($5.51) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
29.86K 220.04K 1.87M 64.35K 7.32M 8.77M 11.78M 13.41M 15.94M 17.15M 19.43M
Normalized Net Operating Profit after Tax (NOPAT)
-15 -13 -11 -16 -11 -20 -23 -34 -29 -30 -39
Normalized NOPAT Margin
-602.16% -582.03% -385.82% -609.45% -462.65% -991.35% -703.55% -627.09% -422.74% -219.84% -225.15%
Pre Tax Income Margin
-601.89% -3,567.75% -562.76% -938.50% -730.84% -1,466.87% -1,002.80% -871.63% -584.39% -303.84% -313.31%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -51.82 0.00 -7.67 0.00 0.00 -549.03 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 -36.17 0.00 -5.37 0.00 0.00 -379.78 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 -51.85 0.00 -7.68 0.00 0.00 -570.09 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 -36.20 0.00 -5.37 0.00 0.00 -400.83 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% -2.01% -2.22% -2.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -2.01% -2.22% -2.31% -2.31% -7.31% -6.00% -11.09% -7.27% -4.89% -4.32%

Financials Breakdown Chart

Key Financial Trends

Tonix Pharmaceuticals (NASDAQ: TNXP) is growing revenue, but it remains heavily dependent on equity financing to fund substantial operating losses. The company’s Q2 2026 results showed revenue of $13.5 million, up from $2.0 million in Q2 2025 and $2.2 million in Q2 2024. Gross profit also improved to $12.8 million, representing an approximately 95% gross margin, compared with negative gross profit in Q2 2025 and Q2 2024.

Despite the stronger top line, operating expenses remain far above revenue. Selling, general and administrative expense rose to $36.0 million in Q2 2026, while research and development expense was $19.4 million. As a result, operating losses remained substantial at $42.5 million, and net loss was $40.6 million. The quarterly net loss has generally worsened from approximately $14.2 million in Q3 2024 and $16.8 million in Q1 2025, although it improved from the $46.9 million loss reported in Q4 2025.

Cash flow trends remain a central concern. Tonix used $42.2 million in operating cash during Q2 2026, following operating cash outflows of $42.3 million in Q1 2026 and $39.7 million in Q4 2025. Financing activities provided $33.5 million in Q2, primarily through common-stock issuance, but that was not enough to offset operating and investing outflows. Cash and equivalents declined to $176.2 million from $185.5 million at the end of Q1 2026.

The balance sheet is relatively strong in terms of liquidity and leverage. Tonix reported $203.4 million in current assets against $30.8 million in current liabilities, and total liabilities were only $31.8 million. The company reported no preferred stock and no meaningful debt balances in the latest periods. However, retained earnings were negative $935.5 million, reflecting the cumulative losses generated by the business.

  • Revenue is expanding rapidly: Q2 2026 revenue of $13.5 million was more than six times Q2 2025 revenue and substantially above the $2.6 million reported in Q3 2024.
  • Gross profitability has improved: Gross profit reached $12.8 million in Q2 2026, compared with a gross loss of $1.3 million in Q2 2025 and a gross loss of $1.2 million in Q2 2024.
  • Liquidity remains substantial: Tonix held $176.2 million in cash and equivalents at June 30, 2026, supported by more than $200 million in current assets.
  • Leverage is limited: Total liabilities were $31.8 million, and the latest balance sheet does not show significant short- or long-term debt, reducing interest-rate and repayment pressure.
  • Interest income is providing some support: Tonix generated $1.4 million of interest and investment income in Q2 2026, but this was small compared with its $42.5 million operating loss.
  • Reported figures include restatements: Several 2024 and 2025 income statement and cash flow figures were restated or calculated, so investors should rely on the latest filings when comparing historical periods.
  • Operating cash burn remains high: Cash used in operations exceeded $39 million in each of the last three reported quarters, including $42.2 million in Q2 2026.
  • Profitability remains distant: Q2 2026 operating expenses of $55.4 million were more than four times gross profit, producing a $42.5 million operating loss despite the improvement in revenue.
  • Equity financing is a recurring funding source: Tonix raised $33.4 million through common-equity issuance in Q2 2026, following $20.2 million in Q1 2026 and $66.95 million in Q4 2025.
  • Dilution risk is significant: Common stock on the balance sheet increased from $736.7 million in Q2 2024 to $1.16 billion in Q2 2026, while weighted-average basic shares rose from 7.3 million in Q2 2025 to 16.6 million in Q2 2026.

Overall, TNXP’s financial profile shows meaningful commercial progress through higher revenue and sharply improved gross margins, but the company has not yet demonstrated operating leverage. Continued losses, substantial cash consumption and repeated equity issuance create dilution and financing risks. The cash balance provides a buffer, but investors should closely monitor whether revenue growth can eventually outpace research, development and corporate spending.

11/18/26 05:44 PM ETAI Generated. May Contain Errors.

Tonix Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tonix Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Tonix Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$124.02 million in 2025, falling from -$48.05 million in 2015. The previous period was -$130.04 million in 2024. View Tonix Pharmaceuticals' forecast to see where analysts expect Tonix Pharmaceuticals to go next.

Tonix Pharmaceuticals' total operating income in 2025 was -$125.70 million, based on the following breakdown:
  • Total Gross Profit: $6.47 million
  • Total Operating Expenses: $132.17 million

Over the last 10 years, Tonix Pharmaceuticals' total revenue changed from $0.00 in 2015 to $13.11 million in 2025, a change of 1,310,700,000.0%.

In the past 12 quarters, Tonix Pharmaceuticals' cash and equivalents has ranged from $4.16 million in Q2 2024 to $190.06 million in Q3 2025, and is currently $162.79 million as of their latest financial filing in Q3 2026.

Tonix Pharmaceuticals had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and none in 2015.

Over the last 10 years, Tonix Pharmaceuticals' book value per share changed from 2.14 in 2015 to 20.82 in 2025, a change of 873.7%.



Financial statements for NASDAQ:TNXP last updated on 11/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners